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Hepatitis C is a blood-borne virus that mainly affects the liver. The infection is often 
contracted early in life and remains as an asymptomatic slowly progressive disease. The 
World Health Organization (WHO) has set a goal to eliminate the hepatitis C virus (HCV) 
infection in 2030 and in order to reach that, anti-HCV screening is encouraged worldwide. In 
Sweden, treatment of HCV has been shown to be cost-effective, so the question is not if HCV 
should be treated but rather how those infected should be identified. The aim of this thesis 
was to study the prevalence, risk factors, and implications for hepatitis C screening in 
different groups of individuals. 
In paper I 7,473 individuals were tested for HCV in a screening campaign. We found an 
anti-HCV prevalence of 1.8% and a prevalence of chronic hepatitis C of 1.4%. The majority 
were women transfused due to childbirth. Younger patients were significantly more often 
started on treatment but no correlation between treatment outcome and age at transfusion was 
found. Screening of individuals with earlier blood transfusion should be continued. 
In paper II 5,135 individuals, 4,108 pregnant women and 1,027 partners were tested for 
HCV at antenatal care clinics. We found an anti-HCV prevalence of 0.7% and a prevalence 
of chronic hepatitis C of 0.4%, in this group of young adults, mean age 30 years. In this study 
all were both tested for HCV and asked about different risk factors using a questionnaire. 
Based on our findings, risk factor-based screening at antenatal care clinics can be used to 
identify HCV infected women and partners who would benefit from subsequent therapy. The 
most relevant targeted screening model is to ask for previous or ongoing drug use, blood 
transfusions, origin in a high-prevalence country, and having a partner with HCV infection. 
In paper III the impact of kidney disease was investigated. Out of 42,522 diagnosed HCV 
individuals, 1,077 were found to have a concomitant chronic kidney disease (CKD), and 268 
required haemodialysis. In the haemodialysis group, 17% of patients were treated for HCV 
and survival was significantly higher in the treated cohort compared to the untreated. This 
study demonstrates that patients with HCV have a higher risk of CKD and need for dialysis 
and that it is possible to treat patients on haemodialysis with interferon and ribavirin with 
improved survival. 
In paper IV we model the cost-effectiveness of universal screening of pregnant women 
compared to risk factor-based screening. This study is based on data from study II, including 
4,108 pregnant women. The main finding of this study is that universal screening can be 
recommended instead of risk factor-based screening for cost-saving reasons in a Swedish 
setting, as long as the cost for the screening test is below the cost for the time spent on 
questions about risk factors at the antenatal care clinic. 
To conclude, our studies have resulted in an increased knowledge about the prevalence of 
hepatitis C in Sweden. The screening strategies need to be renewed, with universal screening 
or improved risk factor-based screening in different groups of the population, including 
analysis of cost-effectiveness. To achieve the goal proposed by the WHO we need to identify 
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Morbidity and mortality due to hepatitis C virus (HCV) infection continue to increase. Viral 
hepatitis, including hepatitis B and C, are among the top ten leading causes of mortality in the 
world. More than 1.3 million individuals die every year due to viral hepatitis (1). The highest 
prevalence is in Eastern Europe and Central Asia (2). Most recent calculations indicate that 
about 70 million individuals are infected with chronic hepatitis C in the world (2). In Sweden 
the prevalence is estimated to be 0.5% but in the population born in the 1950s and 1960s it is 
estimated at 1% (3). Approximately 40,000 individuals are infected in Sweden and about 
1,600 new cases were reported to the Public Health Agency in 2018 (4, 5). 
During the last few years, new and more tolerable drugs have been developed with cure rates 
of >95%. This is one of the greatest medical advances in decades. The World Health 
Organization (WHO) has set an ambitious goal, “Viral hepatitis Strategy”, to eliminate HCV 
as a major public health threat by 2030. Between 2015 and 2030, the WHO targets include 
reducing new HCV infections by 90%, the number of deaths caused by HCV by 65%, and 
increasing the number of eligible persons receiving HCV treatment to 80% (6). 
Since most of the infections with HCV are asymptomatic, screening is a tool to identify 
individuals at risk of liver disease and who might benefit from treatment. To reach the targets 
of the WHO, different types of screening are needed, as well as safe blood transfusions, safe 
injections through harm reduction with needle exchange programs, increased number of 
needles per people who inject drugs (PWID), and treatment is needed to be eligible for all 




2 HEPATITIS C 
2.1 BACKGROUND 
Hepatitis C virus (HCV) is a blood-borne infection discovered in 1989 (7). Reliable 
diagnostic methods have been available since 1990. Blood donor screening for hepatitis C, by 
antibody testing, was introduced in Sweden by January 1st 1992. In countries where blood 
supply screening is or was suboptimal the risk of transmission remains, and also due to poor 
hygienic practices there is still a risk for iatrogenic spread. 
The hepatitis C virus is a small, enveloped RNA virus belonging to the Flaviviridae family, 
genus Hepacivirus. The hepatitis C virus infects the hepatocytes causing liver disease in 
humans, including acute or chronic hepatitis, cirrhosis, and hepatocellular carcinoma.  
 
2.2 EPIDEMIOLOGY OF HCV INFECTION 
HCV increased in the population in Sweden in the late 1960s and 1970s, as a result of 
increased injection drug use (IDU) (3). The highest risk of blood transfusion-transmitted 
HCV infection was between 1970 and 1985, especially if multiple transfusions were given 
(8). Estimation of the anti-HCV prevalence was performed in 1991, showing a prevalence of 
0.1–0.3% in Swedish blood donors, but no recent estimation has been done (9). The 
prevalence of chronic hepatitis C in Sweden is estimated to be 0.5%, from 0.1% in blood 
donors up to 4.4% in patients after open heart surgery (10). 
 
Figure 1 Estimated viraemic HCV prevalence in 2015 Source: Centers for Disease Control and 
Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University 
Press; 2017. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of 




In 2010 the WHO established a document listing 46 different countries with an anti-HCV 
prevalence higher than 3% (11). Egypt has the highest prevalence in the world due to 
nationwide mass anti-schistosomal treatment campaigns with injections almost exclusively 
using unsterilized and shared syringes and needles. This represents the largest ever 
nosocomial spread of blood-borne infection (12). A large study in the Nile Delta in 1996 
found an anti-HCV prevalence of 24% and viraemic HCV prevalence of 15% among 3,999 
examined individuals, with a prevalence in adults >40% (13).  
Populations at increased risk of HCV infection include: 
• people who inject drugs (PWID) 
• recipients of infected blood products (in Sweden before 1992) 
• children born to mothers infected with HCV  
• men who have sex with men (MSM) 
• people with HIV infection 
• prisoners or previously incarcerated persons 
• dialysis patients 
• unexplained elevation of ALT or AST 
 
Due to European Association for the Study of the Liver (EASL) guidelines, screening 
strategies for HCV infection should be defined within national plans based on the local 
epidemiology of HCV infection (14). 
Injection drug use (IDU) is presently the most common route of transmission in Sweden. 
Over 80% of injection drug users have antibodies against HCV, whereof 75% have detectable 
HCV RNA, which is higher compared to what is reported from other parts of the world (15-
17). A systematic review of global HCV infection published in 2017 estimated the prevalence 
among PWID in the United States to be 53% (18). 
Other routes of transmission are blood transfusion before 1992 and vertical transmission from 
mother to child (19, 20). In one meta-analysis the estimated risk of mother-to-child 
transmission (MTCT) was 5.8%, and it is the primary route of paediatric HCV infection (21). 
High viral load and co-infection with HIV are the main risk factors for MTCT. 
The risk of transmission from sexual contacts is not really known. Studies have reported 
extremely low risk or even null within heterosexual couples (22, 23). The risk increases for 
individuals who have more than one sex partner, among men who have sex with men 
(MSM), co-infection with another sexually transmitted disease, or are infected with HIV.  
There is no risk of infection from urine or sweat from an infected individual and there is no 
transmission of hepatitis C virus through food or water. This means that regular contact and 
living with someone who has the virus is not a risk. This means that no one should be 
excluded from work or school because of hepatitis C (24). 
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Less than 50% of chronically infected adults in the United States are reported to be aware of 
their diagnosis and the rate is even lower among children (25). In Sweden some 80% are 
estimated to be aware of their diagnosis, but self-reported HCV status differs from the actual 
status in many cases both in positive and negative individuals (26). A Swedish study of 1,500 
PWID showed that the awareness of having HCV or not was lacking in a large segment of 
individuals in this group (16). 
In Stockholm, during 2018, 364 men and 180 women were newly reported with HCV. The 
majority were 20-49 years old. The transmission route was reported in 287 individuals and 
the distribution was 67% IDU, 8% blood or blood products, 5% heterosexual and 3% 
homosexual transmission (27).  
 
2.3 DIAGNOSIS OF HCV INFECTION 
Anti-HCV, HCV RNA, HCV antigen 
Hepatitis C infection is diagnosed using an antibody test performed with ELISA technique. 
The incubation period for hepatitis C is 1-3(6) months but anti-HCV can be detected as soon 
as 2-12 weeks after transmission in immunocompetent individuals. To diagnose chronic 
infection a positive antibody test should be followed by a confirmatory PCR test detecting 
HCV RNA.  In non-immunocompetent individuals the seroconversion can be delayed. HCV 
RNA can be detected as soon as one week after transmission and is therefore a preferably 
used diagnostic tool in non-immunocompetent individuals.  HCV antigen in serum or plasma 
is a cost-effective marker of HCV replication and is often performed in low- and middle-
income areas (14).  
Rapid diagnostic test 
Rapid diagnostic test (RDT) for anti-HCV have advantages in special settings since the 
individual receives the answer immediately and the contact with the patient is not lost during 
the waiting period for the test result. RDT can use serum or plasma, but there are even easier 
tests using capillary blood or oral fluid (28). 
Plasma viral load, genotype 
In Sweden today, when the diagnosis of chronic hepatitis C is established, tests for plasma 
viral load and genotype are performed. HCV genotype should be determined before initiating 
therapy because it affects the choice and duration of treatment.  
There are seven different genotypes (29). In Sweden genotype 1a and genotype 3a are most 
common, 35% and 31% respectively followed by genotype 2 with 17%, while only 6% have 
genotype 1b (30). Genotype 3 is relatively more frequent among individuals infected by 
injection drug use. In a study on HCV infection among childhood cancer survivors in 
Stockholm, Sweden, a high proportion of genotype 2 was found (31). This can be explained 
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by genotype 2 being the most frequent genotype among blood donors with HCV infection 
acquired by previous blood transfusion, suggesting that this genotype used to be more 
common among blood donors in the 1970s and 1980s.  
In Sweden the distribution of genotypes differs from other parts of the world, with a lower 
frequency of genotype 1 and a higher frequency of genotype 3. Genotype 1 is the most 
common HCV genotype in the United States, accounting for approximately 70% of prevalent 
cases (32, 33). The reasons for the different distribution of genotypes in Sweden, compared 
with other countries is unknown, but could be due to a relatively recent introduction of HCV 
into the population, or a different pattern of transmission. 
 
2.4 EVALUATION OF FIBROSIS STAGE 
Evaluation of the fibrosis stage is recommended to be performed in all patients with chronic 
HCV infection. Previously, liver biopsy was mandatory to evaluate the grade of inflammation 
and the fibrosis stage. During the last ten years this procedure has to a great extent been 
replaced by non-invasive liver elasticity measurement (34-36). The method mostly used in 
Sweden is by FibroScan® and the result is obtained in kilo Pascal (kPa). Using liver elasticity 
measurement, the absence of fibrosis as well as the presence of cirrhosis can be diagnosed 
with reasonably high accuracy. Non-invasive liver elasticity measurement has some 
limitations such as obesity, high ALT levels, or post-prandial testing (14). 
To evaluate the function of the liver, chemical blood samples including ALT, albumin, 
prothrombin-INR and platelet count are performed. Biochemical markers are used in different 
risk scores such as Göteborg University Cirrhosis Index (GUCI) score, aspartate 
aminotransferase (AST) to platelet ratio index (APRI) and fibrosis-4 (FIB-4) (37-39). 
Using a combination of validated blood biomarkers and liver elasticity measurement together 
will provide a sufficient estimate (40).  
Both liver biopsy and non-invasive fibrosis evaluations utilize the same protocols of fibrosis 
stages suggested by Batts and Ludwig or Metavir (41, 42), F0 corresponding to normal liver 
histology, F1 is mild portal fibrosis, F2 periportal fibrosis, F3 bridging fibrosis and F4 
cirrhosis. However, liver biopsy is still the best method to differentiate fibrosis stage F2 and 
F3 (43).  
The severity of the disease in cirrhotic patients should also be evaluated according to the 
Child-Pugh scoring system, based on bilirubin, albumin, prothrombin-INR and the presence 
of ascites or hepatic encephalopathy. The stages are divided into Child-Pugh A (compensated 
cirrhosis), B and C (different levels of decompensation) (44).  
Those patients found to have cirrhosis should be included in hepatocellular carcinoma (HCC) 
surveillance (43).  Ultrasound, as a screening method, should be done every six months to 
identify focal lesions in the liver. If the elasticity measure is above 20 kPa and platelet count 
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below 150 (x109/L) the evaluation should also include gastrointestinal endoscopy to check for 
oesophageal varices. 
 
2.5 HEPATITIS C THE INFECTION 
The incubation period is about 7 (2-26) weeks, but only about 15-20% of those with acute 
hepatitis C infection develop symptoms, consisting of fatigue, abdominal pain, poor appetite, 
or jaundice (45-47). 
Approximately 15-25% of people who are infected with HCV clear the infection 
spontaneously without therapy and do not develop chronic infection. The mechanism for this 
is not fully understood. There are studies showing clearance in as many as 45% of infected 
infants and young women (48, 49). Thus, younger age at the time of infection, female gender 
and patients who do develop symptoms such as jaundice have a higher likelihood of 
spontaneous viral clearance than do asymptomatic patients (47). However, an estimated 75-
85% of those infected with HCV develop a chronic infection (50, 51).   
Usually the progression to advanced liver disease is very slow (52, 53). However, 
approximately 20% of those with chronic HCV progress to cirrhosis within 20 years from 
onset of infection, a proportion which tends to increase with age (54).  
When cirrhosis has occurred the individual has an elevated risk for complications such as 
liver decompensation including portal hypertension with oesophageal varices, ascites, and 
hepatic encephalopathy. Cirrhosis is also associated with an increased risk of developing 
hepatocellular carcinoma (HCC) with a yearly risk of 3-4% (55). HCV is a leading cause of 
HCC worldwide and the morbidity and mortality from HCV-associated HCC is increasing in 
many countries, especially in high-income areas (14). In Sweden in 2018, 244 individuals 
died from HCC, with any etiology (56). After successful treatment with interferon (INF) and 
ribavirin the yearly risk for HCC decreased to 1% in cirrhotic patients (43).  
Chronic HCV infection with complications used to be a common indication for liver 
transplantation in Sweden. In 2011, 150 liver transplantations were done, of which about 25% 
were because of HCV (57, 58). After the introduction of new antiviral therapy in 2014 the 
proportion of HCV infection among liver transplant recipients has decreased to 3-4% in 2019. 
The development of HCV-related liver disease is accelerated in liver transplant recipients 
without effective antiviral treatment and approximately one-third of them develop cirrhosis in 




2.6 TREATMENT OF HCV INFECTION 
For many years the standard of care (SOC) therapy for hepatitis C consisted of pegylated 
interferon (IFN), administered once weekly together with daily oral ribavirin (RBV) for 24 to 
48 weeks, sometimes extended to 72 weeks (59).  
In individuals with HCV genotype 2 or 3 this therapy was quite successful but in patients 
infected with HCV genotype 1 or 4, only half of treated individuals achieved sustained 
virological response (SVR), defined as negative HCV RNA 24 or 48 weeks after end of 
treatment (60, 61).  
This treatment was associated with severe side effects (62). Many patients had to stop the 
treatment because of unbearable side effects and only a few individuals could go on working 
during the treatment period. For interferon the most common side effects are flu-like 
symptoms such as fatigue, fever, chills, headache and muscle ache, depression and psychosis, 
and for ribavirin anaemia, dry skin, rash or eczema. Several groups of patients with co-
morbidities were therefore excluded from treatment because of increased risk of side effects. 
Individuals with ongoing IDU were also excluded. Patients with cirrhosis had a high risk of 
liver-related complications and had a lower treatment response rate. In Sweden, during this 
period about 1,000 patients were treated annually, with a total of 10,000-15,000 patients 
treated with an estimated 40-50% cure rate (61, 63, 64). 
In 2011 the first generation direct-acting antivirals (DAA), telaprevir and boceprevir, were 
approved. With these the treatment was more effective but some patients had severe side 
effects and severe adverse events (65, 66). 
Since 2014 several new agents have been introduced that are more effective and more 
tolerable. Different combinations of protease inhibitors (PI), NS5A inhibitors and nucleoside 
analogues (NUC) are used. The new generation DAA has few contraindications and few side 
effects such as mild headache and nausea. Discontinuations due to adverse events are very 
few (67). There are some interactions to consider before starting the treatment, for example 
anti-coagulants, statins, proton pump inhibitors (PPI) and anti-epileptics. The treatment is 
given orally, 1-3 tablets daily, for eight or twelve weeks. Treatment with new DAA is easy, 
safe and well tolerated and has a cure rate of >95%, defined as negative HCV RNA 12 weeks 
after the end of treatment (43). 
Before initiating treatment, an individual pre-treatment evaluation is performed including 
viral load, genotype, estimation of liver fibrosis, tests for HBV and HIV, checking for drug-
drug interaction and considering compliance. 
Treatment regimens including a protease inhibitor (PI) should not be used in patients with 
Child-Pugh B or C decompensated cirrhosis or in patients with previous episodes of 
decompensation. In patients with cirrhosis, HCC-surveillance should be continued even after 
the patient has achieved SVR because the risk for HCC will only be reduced. With the older 
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treatment the yearly risk reduced from 5 to 1% but with the new DAA it is not yet well 
known (68).   
Neither natural clearing of the virus or successful treatment make an individual immune to 
hepatitis C, all individuals can be re-infected with HCV.  
The production cost of DAAs is low but in many high- and upper middle-income countries 
the treatment remains expensive.  Due to the introduction of generic versions the price is 
much lower in some low-income countries.  
 
2.7 COST-EFFECTIVENESS 
Worldwide, an increasing number of patients with cirrhosis will develop end-stage liver 
disease (ESLD) and HCC. With early treatment disease progression can be avoided. Early 
treatment for hepatitis C is argued to be highly cost-effective when compared to treatment 
initiated at advanced stages of disease. There are a large number of patients in need of 
treatment and early treatment would permit the use of shorter treatment and will reduce the 
cost of treating each patient. 
A systematic review showed evidence of economic benefit for screening populations such as 
birth cohorts, drug users, and high-risk populations (69). Recently a study at a London centre 
showed that routine antenatal screening can be cost-effective (70). The prevalence among 
pregnant women doubled in the United States from 2009 to 2014 and a study from January 
2019 concluded that universal screening for HCV among pregnant women is cost-effective 
and should be recommended nationally (71). In Sweden treatment of HCV has been shown to 
be cost-effective and since January 2018 there are no restriction for antiviral treatment 
regardless of fibrosis stage and for example ongoing IDU (72). 
 
2.8 ACTION FOR ELIMINATION 
There is a remarkable lack of global awareness and action to avoid and combat the disease. 
On World Hepatitis Day which take place yearly on the 28th of July the WHO draws 
attention to the major importance of viral hepatitis in public health. According to the WHO, 
in 2015, of the 70 million individuals living with HCV infection only 20% (14 million) were 
aware of their diagnosis. Only 7.4% of those diagnosed (1.1 million) were started on 
treatment. Of those started on treatment, about half received DAAs. Much more needs to be 
done to achieve the target by 2030. 
There are some positive examples of countries working hard towards elimination. For 
example, Egypt has introduced a national plan and program for managing HCV, which has 
been successful so far in treating a large number of patients, with the aim of achieving disease 
control (73).  
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India has used generic treatment which has enabled antiviral treatment at a lower cost (74).  
Iceland started a national program in January 2016, including universal access to DAA for all 
individuals with chronic HCV, especially PWID and patients with advanced liver disease. 
They also intensified the work with harm reduction and improved linkage to care (75).  
Ten years ago, Scotland started a national scale-up of interventions on hepatitis C among 
PWID. The conclusion was that most of the decline in HCV incidence in Scotland between 
2008 and 2015 was because of the increase of opioid substitution therapy and needle and 
syringe provision due to government strategies on HCV and drugs (76).  
In Sweden a national plan is currently lacking but is underway. There are projects ongoing to 
trace previously identified positive individuals, to treat PWID and individuals on opioid 
substitution therapy and to treat incarcerated individuals (77). 
Many more countries are working on the development of national hepatitis elimination 
strategies heading for expanding prevention, screening, and treatment, resulting in a more 
rapid decline in the total number of patients with viraemic infections.  
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3 HEPATITIS C AND PREGNANCY 
In Sweden there are few reports on anti-HCV prevalence in pregnant women. In a study from 
Gothenburg an anti-HCV prevalence of 0.8% in 1994 was found (78). A study in a London 
centre found the same prevalence (79). In different European countries the anti-HCV 
prevalence is reported to be 0.4-5.2% (80). In the United States the reported prevalence is 
between 1-2.5% but up to 8% in some states (81-83). The prevalence among pregnant women 
doubled from 2009 to 2014 in the United States and 29,000 pregnant women with HCV give 
birth to 1,700 infected neonates every year (84, 85). Worldwide the prevalence is reported to 
be up to 8% (86, 87). 
The epidemiology of hepatitis C has changed from previously being an infection mostly in 
older patients to now affecting younger people, including women of childbearing age 
(WOCA), one explanation being the reports from the United States of a tremendous increase 
in IDU in young adults and teenagers (25, 85). The latest American Association for the Study 
of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidelines 
recommend universal screening of pregnant women (88). Their advice is motivated by this 
change in epidemiology, and the need of change of obstetrical practices such as avoiding 
foetal scalp monitoring, prolonged rupture of membranes if known HCV, the introduction of 
highly effective antiviral treatment after delivery and early identification of infants at risk 
(89).  
Interferon (INF) sometimes with severe side effects and ribavirin with its teratogenic 
potential are no longer used as treatment for HCV in adults in Sweden. Currently, treatment 
for hepatitis C cannot be initiating until after delivery. However, effective therapy after 
delivery provides benefits for subsequent pregnancies, in one study 23% of the women had 
multiple pregnancies over the three years of the period of the study and treatment after 
delivery eliminated MTCT risk in future pregnancies (25, 90). 
The first small phase I study with new direct-acting antivirals (DAA) during pregnancy has 
just been completed but the results are pending (91). If DAA would be proven safe during 
pregnancy, women can be treated during eight to twelve weeks in late pregnancy prior to 
delivery and the risk of MTCT would most probably be eliminated and the newborns will not 
need to be followed. 
While waiting for the results from ongoing studies of antiviral treatment during pregnancy it 
is possible to treat children as young as three years old with different combinations of therapy 
(92-94). However, current Swedish guidelines recommend DAA treatment from the age of 12 
years. 
After the implementation of universal testing of blood products, transmission from mother to 
child became the leading source of HCV infection in children. In one meta-analysis the 
estimated risk of transmission was shown to be 5.8% (21). Delivery by caesarean section is 
not associated with a lower risk of transmission and is not recommended (95). In addition, 
there are no recommendations against breastfeeding (96, 97). An earlier delivery of a child 
 
12 
infected perinatally with HCV does not increase the risk of transmission in subsequent 
pregnancies of the same infected mother (98). 
Children born to HCV positive mothers should be tested for anti-HCV at the age of 18 
months. Up until that time-point detected anti-HCV can come from the mother. If diagnosis is 
of interest at a younger age, before the child reaches 18 months, testing for HCV RNA can be 
performed. HCV RNA testing should then be repeated at a subsequent visit, independent of 
the initial HCV RNA test result (97, 99). 
Pregnancy represents a unique time during which young, otherwise healthy adults may 
actively engage in medical care. Many of these women are hard to reach for testing and 
follow-up often because of drug abuse. However, the compliance of pregnant women is often 




4 HEPATITIS C AND RENAL DISEASE 
Hepatitis C virus infection affects many organs, above all the liver but also the kidneys. 
Patients with HCV have a higher risk of chronic kidney disease and end-stage renal disease 
(ESRD), and less survival of kidney grafts after transplantation (100). HCV can also be a 
complication of kidney disease because of earlier transmission within dialysis units. In the 
early 1990s, once diagnostic testing for HCV became available a high prevalence of 
hepatitis C virus (HCV) in the chronic kidney disease (CKD) population was recognized.  
Still, in 2013 the prevalence of HCV in Swedish dialysis patients was 3-4%, compared to 
the estimated general prevalence of 0.5%. An even higher prevalence, 7.7% was found in a 
multicentre survey in France, and it seems to be associated with the time on haemodialysis 
(101). Given these findings it is important to screen HCV patients for kidney disease and the 
other way around, CKD for HCV. Screening for HCV is recommended on initiation of 
haemodialysis or at transfer to a new dialysis facility or modality (102). 
HCV-positive CKD patients should be evaluated for therapy (103). With the earlier available 
treatment with interferon and ribavirin only few CKD patients, especially if on 
haemodialysis, were treated because of the toxicity of the combination. After an HCV-
infected patient had undergone kidney transplantation, IFN-based treatments were not 
recommended owing to the high risk of graft rejection. The new DAAs are effective, well-
tolerated, and only on occasion need dose reductions in CKD patients. Kidney Disease 
Improving Global Outcomes (KDIGO) recommend that the choice of regimen should be 
based on HCV genotype, prior treatment history, drug–drug interactions, glomerular filtration 
rate (GFR), fibrosis stage, liver transplant candidacy, and comorbidities (102). 
Patients with CKD stage V (GFR <15 (ml/min/1,73 m2)) should be evaluated for kidney 
transplantation, regardless of HCV status. All kidney transplant candidates with HCV should 
be evaluated for DAA-based therapy, before or after transplantation. Survival is shown to be 
greater in kidney transplant recipients compared to those remaining on dialysis (104). 
Survival of the graft is decreased in HCV positive patients. However, with the introduction of 
DAA, the question is when to start HCV therapy in relationship to transplantation (105). In 
patients with decompensated cirrhosis it is preferred to do a combined liver-kidney 
transplantation and postpone treatment. Some centres have started to transplant kidney 
allografts from HCV-positive donors due to a long waiting list. This improves the chances for 
transplantation and treatment can be initiated after the transplantation. This procedure needs a 





The overall aim of this thesis was to study the prevalence, risk factors and implications for 
hepatitis C screening in different groups of individuals. 
5.1 SPECIFIC AIMS 
• To investigate the anti-HCV prevalence in subjects receiving blood transfusions in 
Stockholm and to study what effect age at transfusion has on liver disease and 
proportion who achieved SVR (Paper I). 
• To investigate anti-HCV prevalence in pregnant women in two different Swedish 
counties and to study if general screening at antenatal care clinics could identify 
undiagnosed HCV-infections in both pregnant women and their partners (Paper II). 
• To describe the Swedish HCV patients with CKD and those undergoing HD and to 
investigate the impact of IFN-based treatment on survival in HCV positive patients on 
HD (Paper III). 
• To evaluate cost-effectiveness of universal anti-HCV screening compared to risk 




6 MATERIALS AND METHODS 
6.1 PATIENTS AND STUDY DESIGN 
6.1.1 Paper I 
In this single centre retrospective study in Stockholm County, 7,473 individuals were tested 
for anti-HCV. This was part of a national screening campaign in Sweden in 2008-2010. 
Subjects were informed through media and encouraged to perform anti-HCV testing at their 
local health care center if they had received or thought that they had received blood 
transfusions during the period of 1965-91. The campaign specifically targeted three high-risk 
groups, including individuals who during childhood had been at risk for blood transfusion 
due to heart surgery, cancer treatment or neonatal care. All diagnosed with chronic HCV, 
positive anti-HCV and HCV RNA, were referred to the Department of Infectious Diseases at 
Karolinska University Hospital for follow-up. Inclusion criterion was blood transfusion as the 
most likely mode of HCV transmission, exclusion criterion was ongoing or a history of drug 
use. The HCV RNA positive individuals were divided into two different age groups, young 
and adults, at the time for the blood transfusions. Data on age at transfusion, age at HCV 
diagnosis, genotype, viral load, fibrosis score, liver histology and antiviral treatment was 
recorded.  
6.1.2 Paper II 
In this cross-sectional study anti-HCV prevalence in pregnant women and their partners was 
studied in two different counties in Sweden: Örebro and Stockholm. At their first visit at the 
antenatal care clinic the pregnant woman and her partner were offered anti-HCV screening. 
The study individuals completed a form about characteristics and risk factors for HCV. In 
total 5,135 individuals were tested and of these 4,108 were pregnant women. 
6.1.3 Paper III 
In this retrospective registry-based study 42,522 individuals positive for hepatitis C were 
followed and checked for the development of CKD. Patients were identified for chronic 
hepatitis C and CKD according to the International Classification of Diseases (ICD-10) in the 
nationwide Swedish inpatient day care surgery (1997–2013) and non-primary outpatient care 
(2001–2013) patient registries. Haemodialysis was defined using the code for this procedure 
at least once in the record of the patient. For each patient, up to five comparators without 
hepatitis C, matched on age/sex/place of residency were drawn from the general population at 
the time of diagnosis. Follow-up started at the date when hepatitis C was diagnosed and all 
patients and controls were followed from birth until death, emigration, or the date of 
December 31st, 2013, whichever came first. 
6.1.4 Paper IV 
In this study, we modelled the cost-effectiveness of universal screening of pregnant women 
compared to different levels of risk factor-based screening in Sweden. The model is based on 
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data from study II including 4,108 pregnant women. The differences in cost divided by the 
differences in effect between universal screening and risk factor-based screening was 
estimated, the incremental cost-effectiveness ratio (ICER) (106).  
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝑢𝑛𝑖𝑣𝑒𝑟𝑠𝑎𝑙 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 − 𝐶𝑜𝑠𝑡𝑟𝑖𝑠𝑘 𝑓𝑎𝑐𝑡𝑜𝑟−𝑏𝑎𝑠𝑒𝑑 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔
𝐻𝐶𝑉 𝑐𝑎𝑠𝑒𝑠 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑖𝑒𝑑𝑢𝑛𝑖𝑣𝑒𝑟𝑠𝑎𝑙 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 − 𝐻𝐶𝑉 𝑐𝑎𝑠𝑒𝑠 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑖𝑒𝑑𝑟𝑖𝑠𝑘 𝑓𝑎𝑐𝑡𝑜𝑟−𝑏𝑎𝑠𝑒𝑑 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔
 
To acknowledge uncertainty, sensitivity analysis was performed, both one-way sensitivity 
analysis and probabilistic sensitivity analysis (PSA) by means of Monte Carlo (107). 
 
6.2 METHODS 
6.2.1 Virological methods 
Screening serology of anti-HCV was performed using Abbott Architect Anti-HCV (Abbott 
Laboratories, Abbott Park, IL, USA), confirmed with Inno-LIA HCV Score (Fujirebio 
Europe, Technologiepark 6, Gent, Belgium) or Chiron RIBA HCV 3.0. HCV RNA levels 
were measured by MagNa Pure LC/COBAS TaqMan System or AmpliPrep/COBAS 
TaqMan System (Roche Diagnostics AB). HCV genotype was performed using an in-house 
method (108).  
6.2.2 Biochemical methods 
All biochemical tests were performed using routine methods at the local laboratories. We 
calculated fibrosis index using the Gothenburg University Cirrhosis index (GUCI) score: 
(AST (µkat/L) / TopNormal AST (µkat/L)) * prothrombin-INR * 100 / platelet count 
(x109/L) (37, 109).  
6.2.3 Histological methods 
In order to estimate the fibrosis stage both liver biopsy and non-invasive transient 
elastography were used. Liver biopsies were classified according to Batts and Ludvig. Liver 
stiffness by transient elastography was done using FibroScan® (Echosens, Paris, France). 
6.2.4 Questionnaire 
In paper II a questionnaire was used regarding the characteristics of the study subjects and 
risk factors for HCV such as DU, blood transfusions, partner with HCV, country of origin, 
tattoo or piercing and previous hospital care. The questionnaire was handed to the study 
subjects by the midwife at the antenatal care clinics. 
6.2.5 National registers 
In paper II the National Pregnancy Register (110) was used to compare the characteristics of 
the study population and the background population. 
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In paper III several registers were used, the National Patient Register, Cancer Register, 
Prescribed Drug Register, Total Population Register and Causes of Death Register. The 
coverage in these registers is high due to the universal use of personal identification numbers 
in Sweden. 
6.2.6 HCV treatment 
The standard of care treatment for HCV until December 2013 was pegylated interferon and 
ribavirin. Since January 2014 DAA has been the standard of care treatment in Sweden. 
6.2.7 Statistical methods 
For statistical significance Pearson, Fishers exact or independent t-test was used. In study III 
we used both a univariate regression analysis and presented as odds ratios (OR) and a 
multivariate regression model. Hazard ratios (HR) was calculated using a Cox Regression 
model.  
All reported p-values were 2-sided and a p-value of <0.05 was considered statistically 
significant.  
Statistical analysis was performed with STATA software 13 (Stata Corp. College Station, 
TX, USA) Paper I, SPSS (version 25, 21; IBM Corp, Armonk, NY, USA) Paper II and III, 
TreeAge Pro 2019, R2 (TreeAge Software, Williamstown, MA, USA) Paper IV. 
6.2.8 Ethics 
All studies were performed in accordance to the Helsinki declaration and were approved by 
The Regional Ethical Review Board in Stockholm, Dnr 2011/1372-31/3 (Paper I), Dnr 




7 RESULTS AND DISCUSSION 
7.1 PAPER I 
7.1.1 Prevalence, characteristics and treatment outcome 
Out of 7,473, 134 (1.8%) tested individuals were anti-HCV positive and 102 were HCV RNA 
positive resulting in a prevalence of chronic hepatitis C of 1.4%. The rate of advanced liver 
damage was 18% (10/56). The majority of the infected were women transfused due to 
pregnancy and delivery. Only nine individuals were from the targeted risk groups. There was 
a wide range of age at diagnosis and the oldest one was 92 years old. 
Patients younger than 19 years of age at transfusion were significantly more often started on 
antiviral treatment compared to adult patients, 65% vs 29% p<.001. However, the oldest 
treated patient who achieved SVR was 65 years old. Those infected with genotype 2 and 3 
had a higher rate of SVR, 82% versus 45% p<.018. No significant correlation was found 
between treatment outcome and gender or age at transfusion. 
7.1.2 Blood transfusion as risk factor for hepatitis C 
IDU increased in Sweden in the 1960s and 1970s, and as a result of that, hepatitis C, at that 
time called non-A non-B (NANB) hepatitis, became more prevalent in the 1970s (3, 111). 
When blood donor screening was introduced in 1991, 0.1-0.5% of Swedish blood donors had 
antibodies to HCV (9, 112, 113). In 2006 the number of blood donors in Sweden was 
250,000 and 20 of them were tested positive for anti-HCV in the normal screening (5). 
Today, 3% of the population between the ages of 18-75 years donate blood at least once a 
year (114). 
7.1.3 Screening strategies after blood transfusion 
Most regions in Sweden conducted this campaign only through information to the population 
(115). In Stockholm the information was via newspapers, websites and posters at the local 
health care centres. Active tracing was used in just a few areas of Sweden and reviewing old 
records was considered time consuming and expensive and often not possible due to 
incomplete records.  
Since a relatively low number of individuals were tested in Stockholm during this campaign 
and especially those from the three targeted risk groups, new strategies of finding these 
individuals are needed. In a combined retrospective register based and prospective screening 
study, adults who during childhood (n = 686) had been treated for malignancy in Stockholm 
before 1992, were contacted resulting in testing of 235 patients and of these 11 were HCV-
RNA positive (31). 
As a result of the campaign the recommendations for testing today also include women 
transfused during pregnancy or delivery since this was a group not tested and lacks follow-up 
after blood transfusion (116). 
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Unawareness of previous blood transfusion during childhood is common. Children have a 
higher lifetime risk of HCV-related complications than adults. 
7.1.4 Discussion 
In 2007, the National Board of Health and Welfare in Sweden started this targeted campaign 
for screening of hepatitis C in recipients of blood transfusion (8). At that point it was 
considered relevant to identify blood recipients of potentially hepatitis C-infected blood 
because of better knowledge of complications of hepatitis C and more effective treatment. 
Before initiating the screening campaign the number of individuals from the specific targeted 
risk groups in Stockholm were estimated to be about 12,000 individuals, some 2,000 due to 
heart surgery, 600 to cancer treatment and 9,000 due to neonatal care, respectively (117). It 
was expected that 5% would be anti-HCV positive and of these 75% HCV RNA positive and 
that one third would have known HCV. The campaign in Stockholm resulted in only nine 
newly diagnosed individuals from the defined paediatric risk groups instead of the estimated 
270. 
However, the campaign did find a total of 102 infected individuals of whom a great 
proportion, during the study period and after, successfully have been treated and achieved 
SVR.  
The distribution of men and women differed in this study with more women infected. 
Approximately 60-70% are men in most epidemiological studies which is also reflected in the 
yearly reports from the Public Health Agency (5). Median age at diagnosis in this study is 
higher, since 49% of patients were diagnosed at an age of 61 years or older, compared to 
about 40 in the above yearly reports. 
Since many individuals are not aware of previous blood transfusion and since most 
individuals with hepatitis C are without symptoms we need screening. The screening of 
recipients of blood transfusions during 2007-2010 in Sweden shows that with increased 
testing of risk groups we can identify more cases (5). New screening strategies at antenatal 
care clinics can be seen as a continuation of the national campaign in a place where young 
asymptomatic adults come into contact with healthcare.  
 
7.2 PAPER II AND IV 
7.2.1 Prevalence, risk factors and screening 
In Paper II we found 34 (0.7%) anti-HCV positive individuals (25 women, 9 partners), and of 
these 10 were previously unknown. Risk factors for transmission were DU (n=27), partner 
with known HCV (n=24) and origin from a country outside Sweden (n=8). Chronic infection, 
with positive HCV RNA, was detected in 23 individuals (0.4%). The most effective risk 
factor-based screening model for pregnant women in this study was to ask for DU, blood 
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transfusions, born in a high-prevalence country, and having a partner with HCV, resulting in 
538 (13%) pregnant women tested with 96% sensitivity, 87% specificity.  
The main finding of Paper IV is that universal screening can be recommended instead of risk 
factor-based screening for cost-saving reasons in a Swedish setting. This will be of advantage 
as long as the cost of screening tests is lower than the cost for the time needed for the 
midwife at the antenatal care clinic to interview pregnant women about possible risk factors. 
7.2.2 Universal versus risk factor-based screening 
In paper II both universal screening and a questionnaire concerning risk factors for HCV such 
as DU, previous blood transfusion, ever having a partner with known HCV, country of origin, 
tattoo/piercing and previous hospital care was used. The study subjects were also asked for 
known former HCV status. Based on the answers, different combinations of risk factors were 
investigated and checked for how many individuals needed to be tested with the different 
combinations, and the specificity and sensitivity were calculated. The conclusion was that 
risk factor-based screening at antenatal care clinics can be used to identify HCV-infected 
women and partners who need follow-up and therapy.  
7.2.3 Cost-effectiveness of universal versus risk factor-based screening 
In Sweden, treatment of HCV has been shown to be cost-effective, so the question is not if 
HCV should be treated but rather how those infected should be identified at the lowest 
possible cost (72). In paper II we concluded that risk factor-based screening is possible and in 
paper IV we added cost-effective analysis. To make this calculation the cost of the screening 
test must be compared to the cost of the time used by the midwife to ask several questions 
about possible risk factors. In paper IV we show that as long as the cost for the screening test 
is below the time needed for interviewing the pregnant women, universal screening is a 
dominant strategy and will save costs.  
7.2.4 Discussion 
Pregnant women are already routinely screened for several infectious diseases, but not yet for 
HCV infection (118).  
We need better screening strategies in different groups of the population. Screening at 
antenatal care clinics is one possibility to reach many young individuals, both pregnant 
women and their partners. Both improved risk factor-based screening and universal screening 
are possible alternatives. 
Universal screening for hepatitis C is not at present recommended in pregnant women by the 
European Centre for Disease Prevention and Control (ECDC), Centers for Disease Control 
and Prevention (CDC) or Society for Maternal-Fetal Medicine (SMFM) (89, 119, 120). In the 
latest EASL guidelines from 2018 screening of HCV in pregnancy is not commented on, but 
the latest American Association for the Study of Liver Diseases (AASLD)/Infectious 
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Diseases Society of America (IDSA) guidelines recommend universal screening of pregnant 
women (14, 88).  
Ever since 2010, the Act on Pregnant Woman Care in Poland have implemented anti-HCV 
screening for all pregnant women. Before 2010, 9 % were diagnosed with unknown risk 
factors and after 2010, 46.1 % were diagnosed without risk factors. That large group, without 
risk factors, can only be detected through universal screening examinations (90). 
In paper II it was shown that it is possible to use risk factor-based screening resulting in both 
high sensitivity and specificity. However, risk factor-based screening is not optimal since 
providers often do not ask about risk factors and individuals do not tell. In paper IV it was 
shown that due to cost-effectiveness universal screening is preferred as long as the cost of the 
screening test is lower than the cost for asking about risk factors. 
 
7.3 PAPER III 
7.3.1 Chronic kidney disease in Swedish HCV patients 
Between 2001 and 2013, 2.5% (n=1,077) of the Swedish HCV patients had a reported CKD 
diagnosis. This resulted in a higher incidence of CKD diagnosis within the HCV cohort than 
expected when comparing with the group of matched comparators, 3.84 cases per 1,000 
person-years in the HCV cohort versus 0.97 cases per 1,000 person-years in the comparator 
cohort, resulting in a SIR of 4.0 (95% CI 3.7-4.2).  
7.3.2 Hepatitis C and haemodialysis 
In total 268 HCV patients had ≥1 haemodialysis (HD) procedure code during the study 
period. Almost all HD patients had kidney failure diagnosis. Younger age at initiating of HD, 
receiving either kidney transplantation or HCV treatment, or getting an acute kidney failure 
diagnosis was significantly associated with survival in haemodialysis patients when analysing 
using a univariate regression model. These four factors also independently predicted survival 
when using a multivariate regression analysis.  
The annual prevalence of HCV among haemodialysis patients in Sweden was between 3% 
and 4% for the years 2010 through 2013. The overall chronic HCV prevalence in Sweden is 
estimated to be around 0.5%. Of the HD patients 17% (45/268) had received HCV treatment, 
60% (27/45) of these received HCV treatment after initiating HD. In the group of 
haemodialysis patients started on treatment 24% (11/45) died during the study period 
compared to 56% (124/223) in the untreated group. 
7.3.3 HCV treatment in haemodialysis patients 
During the study period SOC was still IFN-based treatment. In this study, 17% (45/268) of 
patients on haemodialysis had received HCV treatment. Treatment before or after start of 
 
22 
haemodialysis did not affect survival, but those receiving treatment had a significant better 
outcome.  
Standard treatment today consists of elbasvir/grazoprevir or glecaprevir/piprentasvir. Both 
combinations can be used regardless of renal function, including haemodialysis patients (121, 
122). These treatments have been shown to be well tolerated and with high cure rates. 
7.3.4 Discussion 
Morbidity and mortality in haemodialysis patients and kidney transplant recipients are 
affected by hepatitis C and liver complications (123). The prevalence of HCV in 
haemodialysis units in high-income countries is declining, but remains high, as high as 70 %, 
in some low-income countries (124). 
In our study the treatment rate in haemodialysis patients was high, 17%. Treatment with 
interferon and ribavirin in patients on haemodialysis, as in other groups of patients is 
associated with a high risk for adverse events and side effects, and the dosing schedules have 
been complicated (125). In an international observational study only 1% of haemodialysis 
patients with HCV had received treatment, as long as the SOC treatment was interferon and 
ribavirin (126). 
HCV is a risk factor for transition from chronic kidney disease to end-stage renal disease 
(ESRD) and the presence of anti-HCV in haemodialysis patients is a risk factor for death, due 
to increased risk of cirrhosis and HCC in this specific group of patients (127, 128). It is also 
shown that haemodialysis can have a negative impact on the course of HCV infection. 
The survival rate for HCV-infected renal transplant recipients is better than in HCV-infected 
haemodialysis patients remaining on transplant waiting lists (129). An explanation for this 
can be that well-functioning renal allografts is decreasing uremic toxins.  
Early diagnosis, treatment of HCV infection with new effective DAA treatment, and kidney 
transplantation prevents complications and reduces mortality. At present all haemodialysis 




8 CONCLUSION AND FUTURE ASPECTS 
These four studies include different groups of individuals with either increased risk for 
hepatitis C or who should benefit from extended screening. 
The anti-HCV prevalence in the nationwide screening campaign in Stockholm, among 
individuals who have received blood transfusion, was higher than in other parts of Sweden. In 
the campaign only few individuals from the three targeted risk groups were identified. 
However, during the study period and after, 59 individuals achieved SVR after treatment, 
decreasing their risk of liver complications. 
Hepatitis C is a global health problem and since most infections are asymptomatic, universal 
or risk factor-based screening is needed. Screening at antenatal care clinics can be used for 
diagnosis of HCV-infection in both pregnant women and partners. Those found to be HCV 
positive can be linked to care for follow-up and effective treatment.  
There is an increased risk of chronic kidney disease and dialysis dependency in patients with 
hepatitis C. In our study antiviral treatment improved survival of patients with hepatitis C on 
haemodialysis. After the introduction of DAA, all haemodialysis patients should be 
considered for receiving treatment to cure the HCV infection. 
To analyze cost-effectiveness of universal screening versus risk factor-based screening the 
cost for the screening test and the cost for the time needed to ask questions about risk factors 
must be included. Under the base-case assumptions, universal screening is a dominant 
strategy, saving costs while giving equal or higher effectiveness. This will be the case as long 
as the cost of screening tests is below the cost for the time used in maternal care to interview 
pregnant women about possible risk factors. 
There is a need for more data on the total burden of hepatitis C in Sweden. The consequences 
of hepatitis C are extensive both for the individual and for the society. To prevent the 
prevalence of HCV from continuing to increase worldwide a global effort is needed. The best 
public health strategy is identification and treatment of as many individuals with chronic 
hepatitis as possible. With the new drugs treatment is simple and should be adopted 
aggressively in order to reduce the prevalence.  
Screening and treatment of PWID is not included in this thesis. To eliminate HCV, as 
proposed by the WHO, increased screening and treatment in this group is crucial. There is a 
need for new guidelines about how often PWID should be screened, with which method and 
further knowledge of reinfections must be obtained. 
In the future, rapid diagnostic tests are needed as well as adequate tests for identification of 
viraemic individuals which will facilitate linkage to care and treatment. Since pan-genotypic 
treatment is available, genotype analysis would be optional or perhaps excluded. 
Measurement of liver elasticity will not be necessary in young individuals with a short 
duration of intravenous drug use and short duration of disease because of a low probability of 
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advanced disease. In these subpopulations eight weeks of treatment is enough to achieve 
SVR. 
To conclude, since hepatitis C often is asymptomatic a great proportion of individuals with 
chronic hepatitis C are unaware of their infection. To be able to identify these individuals, 
extended screening of different groups at risk is required and then correct calculation of 
prevalence and incidence can be done. To be able to reach the worldwide target in 2030 there 




9 SAMMANFATTNING PÅ SVENSKA 
Hepatit C virus smittar via blodet och infekterar levern. Många smittas tidigt i livet och 
utvecklar ofta en kronisk men asymtomatisk infektion som efter hand kan leda till leverfibros, 
skrumplever och levercancer. Eftersom majoriteten inte har några symtom kan man bära på 
infektionen utan att veta om det. Idag är den vanligaste smittvägen via intravenöst missbruk 
då man delar nålar eller annan icke-steril utrustning. Barn kan smittas från modern under 
graviditet och förlossning. Tidigare var även blodtransfusion en risk för smitta men sedan 
1992 kontrolleras allt blod i Sverige. Sedan 2014 finns effektiv behandling mot hepatit C, 
denna består av 1 till 3 tabletter dagligen i 8 till 12 veckor. Behandlingen har väldigt få 
biverkningar och över 95% av behandlade patienter läker ut. Världshälsoorganisationen 
(WHO) har satt som mål att eliminera hepatit C till år 2030. För att uppnå det målet behövs 
ökad kunskap om förekomsten av hepatit C och våra metoder för screening måste förnyas.  
Syftet med den här avhandlingen var att studera förekomsten av hepatit C i olika grupper, 
riskfaktorer för att smittas och utvärdera olika metoder för screening.  
I första studien fann vi en högre förekomst av hepatit C hos individer i Stockholm som fått 
blodtransfusion före 1992 jämfört med allmänheten. Den var också högre jämfört med 
motsvarande grupp i hela Sverige. Studien visade också att yngre individer oftare påbörjade 
behandling mot hepatit C men vi fann ingen skillnad i utläkningsfrekvens beroende på vid 
vilken ålder som blodtransfusionen givits.  
I andra studien testades gravida och deras partners för hepatit C på barnmorskemottagningar i 
Örebro och Stockholm. Andelen infekterade av hepatit C var något högre jämfört med 
tidigare uppskattning av förekomsten i Sveriges befolkning. Vid screening baserad på 
riskfaktorer fann vi att den bästa kombinationen är att fråga om aktuellt eller tidigare 
drogmissbruk, tidigare blodtransfusion, ursprung i land med känd högre förekomst av hepatit 
C och tidigare eller aktuell partner med känd hepatit C. Vår slutsats är att denna metod för 
screening är möjlig för att kunna diagnostisera både gravida och deras partner och därmed 
kunna erbjuda blivande föräldrar med hepatit C vård och behandling. 
I tredje studien användes flera olika register för att beräkna andelen patienter med hepatit C 
som också drabbats av njursvikt och behov av dialys. Vi studerade hur många av de med 
dialys som fick behandling mot hepatit C och dödligheten hos de behandlade jämfört med de 
obehandlade. Vi fann att patienter med hepatit C i högre utsträckning, jämfört med en 
kontrollgrupp utan hepatit C, utvecklade njursvikt och behov av dialys. Andelen 
dialyspatienter, i den här studien, som behandlades var högre än i andra delar av världen och 
de hade en bättre överlevnad.  
Fjärde studien bygger på våra resultat i studie II. Med en kostnadseffektivitetsanalys 
jämfördes kostnad för provtagning av hepatit C hos alla gravida med testning av en del av de 
gravida baserat på frågor om olika riskfaktorer med ökad risk för blodsmitta. Huvudfyndet i 
studien är att så länge priset för blodprovet för hepatit C är lägre än kostnaden för den 
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arbetstid som krävs av barnmorskan att ställa frågor kring faktorer med ökad risk för 
blodsmitta så är generell testning kostnadseffektiv. 
Sammanfattningsvis visar våra resultat att förekomsten av hepatit C i de studerade grupperna 
är något högre än hos allmänheten, screening baserat på riskfaktorer hos gravida är möjligt 
men provtagning av alla gravida kan vara mer kostnadseffektivt. För att nå det uppsatta målet 
från WHO om eliminering behöver vi ha nya riktlinjer för vilka som ska provtas för att vi ska 
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